53 results on '"Ando, G."'
Search Results
2. Have Infliximab Discounted Prices in Norway Had an Impact on Prices Around the World?
3. The Expansion of Use of Discounted Prices for International Reference Pricing Purposes.
4. The Effect of Decentralised Public Health Care Provision on Accessibility To Medicines in Bosnia And Herzegovina.
5. Are Prices of Patent-Protected Pharamceuticals in the Top 5 Eu Countries Converging?
6. Correlation Between End-of-Life Status of A Treatment And Likelihood of A Patient Access Scheme in The Setting of A Nice Review in The UK.
7. An Analysis of the 2014 Moroccan Drug Price Cuts.
8. Market Access Risk Scoring: A Unified Framework for Cross Country Comparison of Diverse Market Access Systems and Processes.
9. Is Drug Innovation Still Rewarded in the Top 5 European Pharmaceutial Markets?
10. The Potential Impact of Amnog-Triggered International Referenc Pricing: A Scenario from DPP-IV Inhibitors.
11. Price Differences Triggered by the Availability of Biosimilars in Developed Countries.
12. Differences in Approach to Biosimilars: Nice Versus SMC Recommendations.
13. PHP47 Impact of Economic and Policy Factors on China'S Health Care Expenditure
14. PCN147 A Cross European Comparison of Eribulin Reimbursement Decisions
15. PHP190 Global Pharmaceutical Risk-Sharing Agreement Trends in 2011 and 2012: Slowing Down?
16. PHP136 Generic Price Linkage As a Policy Choice: Review of Recent Developments
17. PHP11 Availability and Pricing of Innovative Pharmaceuticals in the Top 5 European Pharmaceutical Markets
18. PHP148 Global Pharmaceutical Risk-Sharing Agreement Trends in 2010 and 2011
19. PHP38 Market Access for Pharmaceuticals in UK: Number and Speed of Drug Reviews to Improve After Introduction of Value Based Pricing
20. PHP13 A Survey of Pricing Trends Around the World
21. PHP12 Then and Now: The Evolution of International Reference Pricing Globally
22. Acute thrombosis of the sinus node artery: arrhythmological implications.
23. PDG62 THE CONTINUUM OF INTERNATIONAL REFERENCE PRICING USE IN LATIN AMERICA: A QUALITATIVE ANALYSIS.
24. PHP23 - International Reference Pricing Expands Reach in Leading Latin American Countries.
25. Kazakhstan Verse Uzbekistan: A Review of the Drug Provision Systems.
26. Discrepancy Between National Drug Recommendations And Local Uptake in the Swedish Inpatient Sector.
27. Analysis of New Model of Therapeutic Positioning Reports As A P&R Decision-Making Tool in Spain.
28. The Inverse Correlation Between Internal And External Risk Under International Reference Pricing: An Analysis of Six European Countries.
29. The Evolution of International Reference Pricing: An Analysis of 39 Countries.
30. Impact of 2011 German Health Care Reform on Prices.
31. Analysis of Brazilian Public Funding Process for New Biologic Drugs.
32. A Review of the Application of International Reference Pricing in Ukraine’s Pilot Hypertension Reimbursement Scheme.
33. Draft Versus Final Guidance in Nice’s Drug Technology Appraisal Process.
34. Croatia’s EU Accession in the Context of International Reference Pricing: What Will Be the Wider Impact for Pricing and Reimbursement?
35. Medico-Economic Evaluation in France: Methodology and Impact on the Pricing and Reimbursement System.
36. Characterising Preliminary Profile Paramaters for FDA Breakthrough Therapy Candidates.
37. The Impact of Indication Extensions on Pharmaceutical Prices.
38. The Impact of Amnog on Oncology Drugs.
39. Market Access Lessons From Existing Product Development Partnerships (PDPS).
40. PHP8 A Survey of “Joint Working” Between the Pharmaceutical Industry and the National Health Service in the UK
41. PCV35 Cross-Country Comparison of Treatment Costs with Amiodarone and Propafenone in Arrhythmia
42. PHP33 Impact of 2011 German Health Care Reform on Global Market Access Strategies
43. PHP2 Relation Between Consumer Behaviour and Drug Safety Monitoring in France
44. P29 Reimbursement Outcomes for Combination Therapies vs Monotherapies in Lung Cancer and Multiple Myeloma in the Top Five European Markets.
45. The Evolution of HTA as a Coverage Decision-Making Tool in the Middle East and North Africa Region.
46. Quantitative Assessment of Canadian Provincial Public Funding Decisions for Oncology Drugs Following Pcodr Economic Evaluations for 2013 and 2014.
47. Preliminary Assessment of the Cost of Treatment for Chronic Hepatitis C Virus Infections with Sofosbuvir and First Generation Antivirals Across Eight Countries.
48. Differential Pharmaceutical Pricing: Are Prices Co-Related With GDP?
49. Biosimilar and Originator Biologic Pricing Dynamics in Emerging Markets.
50. The 2012 Price Trend Analysis For 12 Leading Therapy Areas In 12 Selected Developed Adn Emerging Markets.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.